Q-omics provides the consensus-scored TMEM256-PLSCR3 profile across patient tissues and cancer cell-line models. TMEM256-PLSCR3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, TMEM256-PLSCR3 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, TMEM256-PLSCR3 RNA expression shows 15,075 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight THCA, LUAD, and THYM as cancer lineages where TMEM256-PLSCR3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM256-PLSCR3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM256-PLSCR3 survival associations across molecular data types. TMEM256-PLSCR3 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM256-PLSCR3 RNA expression–survival associations across cancer types. High TMEM256-PLSCR3 expression shows unfavorable associations in THCA, LUAD and KICH, but favorable associations in PAAD, KIRC and ESCA. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify THCA as the clearest survival context for TMEM256-PLSCR3 RNA expression.
This table summarizes TMEM256-PLSCR3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM256-PLSCR3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM256-PLSCR3 shows lower tumor expression in LUAD, LIHC, BRCA and THCA and higher tumor expression in KIRP and KIRC. The LUAD box plot shows higher TMEM256-PLSCR3 RNA expression in normal versus tumor tissue (log2 FC = −0.118, t-test p < 0.001).
This table shows molecular features associated with TMEM256-PLSCR3 in patient tissues and cancer cell lines. In patient samples, TMEM256-PLSCR3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM256-PLSCR3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE.
